NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Maybe the MHRA are having a hard time justifying paying big bucks for a GBM vaccine that gives 2.8 months longer median survival for newly diagnosed patients and 5.8 months for recurrent patients.
Okay, the 13% of long tail patients are fantastic, but is it enough to sway MHRA?

The British economy is in a bad place right now, they are talking about tax hikes to fill the big holes they got.

Gus, the MHRA does not evaluate the cost effectiveness of the drug. It is a separate review by NICE that does that,

The NICE process has not yet started as they are waitng for NWBO to submit to them. The NICE evidence submission is complex and very different from the MAA. The guts consist of an economic model that evaluates the cost to NHS vs the QALY Quality Adjusted Life Years gained). This take a lot into consideration, as I said, very complex.

But the MHRA action is 100% independent of the NICE decision.